Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(11):1474–1479. doi: 10.1038/bjc.1997.580

A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.

Y Shibamoto 1, G Ohshio 1, R Hosotani 1, Y Nishimura 1, T Manabe 1, M Imamura 1, M Abe 1
PMCID: PMC2228186  PMID: 9400944

Abstract

A fluorinated 2-nitroimidazole radiosensitizer KU-2285 was given before intraoperative radiotherapy (IORT) to 30 patients with unresectable, unresected or macroscopic residual tumours. Twenty-three patients had pancreatic cancer and five had osteosarcoma. The IORT dose was 30 Gy for unresectable pancreatic cancer and 60 Gy for osteosarcoma. The dose of KU-2285 administered ranged from 1 to 9 g m-2. Four patients received a dose of 9 g m-2, and ten received 6.8-7 g m-2. All patients tolerated KU-2285 well, and no drug-related toxicity was observed. The average tumour concentration of KU-2285 immediately after IORT was 166 microg g-1 at dose of 6.8-7 g m-2 and 333 microg g-1 at 9 g m-2. The average tumour-plasma ratio was > or = 0.82. Eleven patients with unresectable but localized pancreatic cancer treated with KU-2285 plus IORT and external beam radiotherapy had a median survival time of 11 months and 1-year local control rate of 50%, which compares favourably with those of 8 months (P = 0.26) and 28% (P = 0.10) for 22 matched historical control patients. The five patients with osteosarcoma attained local control. The results of this first study on KU-2285 and IORT appear encouraging, and further studies of this compound seem to be warranted.

Full text

PDF
1474

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol. 1993 Feb;26(2):93–103. [PubMed] [Google Scholar]
  2. Adams G. E. Hypoxic cell sensitizers for radiotherapy. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):135–141. doi: 10.1016/0360-3016(78)90129-3. [DOI] [PubMed] [Google Scholar]
  3. Brown J. M. Hypoxic cell radiosensitizers: the end of an era? Regarding Lee et al., IJROBP 32:567-576; 1995. Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):883–885. doi: 10.1016/0360-3016(95)00186-3. [DOI] [PubMed] [Google Scholar]
  4. Coleman C. N., Wasserman T. H., Urtasun R. C., Halsey J., Noll L., Hancock S., Phillips T. L. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03. Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):389–393. doi: 10.1016/0360-3016(90)90105-s. [DOI] [PubMed] [Google Scholar]
  5. Halberg F. E., Cosmatis D., Gunderson L. L., Noyes R. D., Hanks G. R., Buswell L., Nagorney D. M., Coleman C. N. RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies. Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):201–206. doi: 10.1016/0360-3016(94)90158-9. [DOI] [PubMed] [Google Scholar]
  6. Kagiya T., Nishimoto S., Shibamoto Y., Wang J., Zhou L., He Y. L., Sasai K., Takahashi M., Abe M. Importance of tumor affinity of nitroazoles in hypoxic radiosensitization. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1033–1037. doi: 10.1016/0360-3016(89)90910-3. [DOI] [PubMed] [Google Scholar]
  7. Lawton C. A., Coleman C. N., Buzydlowski J. W., Forman J. D., Marcial V. A., DelRowe J. D., Rotman M. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):673–680. doi: 10.1016/s0360-3016(96)00336-7. [DOI] [PubMed] [Google Scholar]
  8. Lee D. J., Cosmatos D., Marcial V. A., Fu K. K., Rotman M., Cooper J. S., Ortiz H. G., Beitler J. J., Abrams R. A., Curran W. J. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):567–576. doi: 10.1016/0360-3016(95)00150-W. [DOI] [PubMed] [Google Scholar]
  9. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509–518. [PubMed] [Google Scholar]
  10. Oya N., Shibamoto Y., Sasai K., Shibata T., Murata R., Takagi T., Iwai H., Suzuki T., Abe M. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):119–127. doi: 10.1016/0360-3016(95)00040-6. [DOI] [PubMed] [Google Scholar]
  11. Oya N., Shibamoto Y., Sasai K., Sugiyama T., Abe M. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1113–1119. doi: 10.1016/0360-3016(93)90532-z. [DOI] [PubMed] [Google Scholar]
  12. Sasai K., Nishimoto S., Shimokawa K., Hisanaga Y., Kitakabu Y., Shibamoto Y., Zhou L., Wang J., Takahashi M., Kagiya T. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1249–1254. doi: 10.1016/0360-3016(91)90235-v. [DOI] [PubMed] [Google Scholar]
  13. Sasai K., Shibamoto Y., Manabe T., Baba N., Takahashi M., Sakaguchi M., Abe M. Pharmacokinetics of intratumoral RK-28, a new hypoxic radiosensitizer. Int J Radiat Oncol Biol Phys. 1992;24(5):959–963. doi: 10.1016/0360-3016(92)90480-6. [DOI] [PubMed] [Google Scholar]
  14. Shibamoto Y., Manabe T., Ohshio G., Sasai K., Nishimura Y., Imamura M., Takahashi M., Abe M. High-dose intraoperative radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):57–63. doi: 10.1016/0360-3016(95)00014-3. [DOI] [PubMed] [Google Scholar]
  15. Shibamoto Y., Nishimoto S., Shimokawa K., Hisanaga Y., Zhou L., Wang J., Sasai K., Takahashi M., Abe M., Kagiya T. Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1045–1048. doi: 10.1016/0360-3016(89)90912-7. [DOI] [PubMed] [Google Scholar]
  16. Shibamoto Y., Nishimura U., Abe M. Intraoperative radiotherapy and hyperthermia for unresectable pancreatic cancer. Hepatogastroenterology. 1996 Mar-Apr;43(8):326–332. [PubMed] [Google Scholar]
  17. Shibamoto Y., Streffer C., Sasai K., Oya N., Abe M. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int J Radiat Biol. 1992 Apr;61(4):473–478. doi: 10.1080/09553009214551231. [DOI] [PubMed] [Google Scholar]
  18. Shibamoto Y., Takahashi M., Abe M. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiother Oncol. 1996 Jul;40(1):55–58. doi: 10.1016/0167-8140(96)01740-9. [DOI] [PubMed] [Google Scholar]
  19. Shibata T., Shibamoto Y., Oya N., Sasai K., Murata R., Ishigaki T., Abe M. Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):587–590. doi: 10.1016/0360-3016(94)90462-6. [DOI] [PubMed] [Google Scholar]
  20. Tepper J. E., Shipley W. U., Warshaw A. L., Nardi G. L., Wood W. C., Orlow E. L. The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol. 1987 Apr;5(4):579–584. doi: 10.1200/JCO.1987.5.4.579. [DOI] [PubMed] [Google Scholar]
  21. Urtasun R. C., Coleman C. N., Wasserman T. H., Phillips T. L. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1691–1696. doi: 10.1016/0360-3016(84)90530-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES